Share on

Latin America Ophthalmic Drugs Market Research Report - Segmented By Therapeutic Class, Product Type, Distribution Channel, Disease Indication, Dosage Form, Technology and Country (Brazil, Mexico, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 5305
Pages: 145
Formats: report pdf report excel report power bi report ppt

Latin America Ophthalmic Drugs Market Size (2022 to 2027)

As per the research report, the Latin American Ophthalmic Drugs market was valued at around USD 4.23 billion in 2022. It is expected to grow at a CAGR of 6.4% and be worth USD 5.77 billion by 2027. It captures 12% of the global market.

An increasing number of people suffering from glaucoma around the region and substantial innovation and funding in the development of combination treatments are driving the growth of the Latin American ophthalmic drugs market. In addition, other factors such as FDA approvals, which raise medication approvals and increase surgeries in the ophthalmology industry due to the high prevalence of reactive defects, are fuelling the market growth.

The market is expanding as the population ages, the incidence of eye disorders increases, healthcare spending rises, and the use of minimally invasive surgeries increases. In addition, the growing patient population in developed and developing countries and rising healthcare spending on eye illness are driving the ophthalmic drug market forward.

As the prevalence of eye problems develops, the demand for ophthalmic medications grows. Eye diseases have already emerged as threats to people’s visual experience in many industrialized and developing countries. As the prevalence of diabetes has increased in many areas, diabetes medicines have been introduced. Glaucoma has been on the public health agenda for millennia due to the difficulties in recognizing it early and the need for long-term treatment.

The long gestation period for new drugs and undesirable side effects impede the expansion of the Latin American ophthalmic drugs market. Furthermore, the market growth is limited by issues like well-known drugs falling off patent and big players being hampered by the time it takes for the new drugs to join the market. In addition, risks associated with ocular disorders and a lack of public understanding of ophthalmology are further estimated to hamper the market’s growth rate.

This research report on the Latin American ophthalmic drugs market has been segmented and sub-segmented into the following categories:

By Therapeutic Class: 

  • Anti-inflammatory Drugs
  • Anti-infective Drugs
  • Anti-glaucoma Drugs
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

By Product Type: 

  • Prescription Drugs
  • Over-the-Counter Drugs 

By Distribution Channel: 

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies
  • Drug Stores 

By Disease Indications: 

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
  • Allergy
  • Uveitis
  • Others  

By Dosage Form: 

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms       

By Technology: 

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others 

By Country: 

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America

The ophthalmic drug market in Latin America is expected to increase steadily during the forecast period. The expanding usage of health insurance is projected to play an essential part in the regional market growth.  Latin America is projected to record a moderate share in the global ophthalmic drugs market in the coming years as the market growth is fueled by the rising number of patients from glaucoma and significant innovation and funding in the development of combination therapy. Also, the expanding prevalence of diabetes and rising healthcare spending drive the Latin American ophthalmic drugs market. The major countries in the region, such as Brazil, Mexico, and Argentina, significantly contribute to regional market growth.

However, the Brazilian ophthalmic drugs market dominated the Latin American market in 2020, which is likely to augment the significant growth over the forecast period. Brazil is investing a considerable amount of capital in healthcare. Although many non-diabetic individuals get cataracts, people with diabetes have a 60% higher probability of developing this eye condition at a younger age and at a faster rate.

Furthermore, according to the World Health Organization (WHO), healthcare expenditure in Argentina accounted for a considerable portion of GDP, indicating that the Argentina government spent a significant amount of money on healthcare, boosting the expansion of the Latin American ophthalmic drugs market.

KEY MARKET PLAYERS:

A few prominent companies operating in the Latin American ophthalmic drugs market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

Please wait. . . . Your request is being processed

FAQ's

What is the size of the Latin America Ophthalmic Drugs Market?

The size of the Latin America Ophthalmic Drugs Market is anticipated to be worth USD 5.777 billion by 2027.

What are some of the key factors driving the growth of the Latin America Ophthalmic Drugs Market?

The growing prevalence of ophthalmic disorders, the increasing aging population, advancements in drug delivery systems, and an increase in healthcare spending in Latin America are propelling the growth of the ophthalmic drugs market in Latin America.

Who are the major players in the Latin America Ophthalmic Drugs Market?

Novartis AG, Allergan, Pfizer, Santen Pharmaceutical Co., Ltd., and Bausch Health Companies Inc. are playing a leading role in the Latin America ophthalmic drugs market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample